| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/13/2023 | 39.86% | Wells Fargo | $2.5 → $2 | Maintains | Overweight |
| 07/12/2023 | 39.86% | Wedbush | → $2 | Downgrades | Outperform → Neutral |
| 03/24/2023 | 249.65% | Mizuho | $6 → $5 | Maintains | Buy |
| 03/24/2023 | 319.58% | Needham | → $6 | Reiterates | → Buy |
| 12/08/2022 | 179.72% | BTIG | → $4 | Upgrades | Neutral → Buy |
| 05/17/2022 | 319.58% | Needham | $8 → $6 | Maintains | Buy |
| 05/11/2022 | 179.72% | Barclays | $6 → $4 | Maintains | Overweight |
| 01/06/2022 | 319.58% | Mizuho | $28 → $6 | Maintains | Buy |
| 01/05/2022 | 319.58% | Barclays | $22 → $6 | Maintains | Overweight |
| 01/05/2022 | 109.79% | Morgan Stanley | $7 → $3 | Maintains | Equal-Weight |
| 01/05/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 01/05/2022 | 459.44% | Needham | $28 → $8 | Maintains | Buy |
| 11/19/2021 | 389.51% | Morgan Stanley | $24 → $7 | Downgrades | Overweight → Equal-Weight |
| 10/12/2021 | 1648.25% | Morgan Stanley | $27 → $25 | Maintains | Overweight |
| 07/16/2021 | 1927.97% | Morgan Stanley | $31 → $29 | Maintains | Overweight |
| 06/15/2021 | 1508.39% | BTIG | → $23 | Initiates Coverage On | → Buy |
| 05/27/2021 | 1858.04% | Needham | → $28 | Maintains | Buy |
| 05/14/2021 | 2067.83% | Morgan Stanley | $34 → $31 | Maintains | Overweight |
| 05/03/2021 | 599.3% | SVB Leerink | $18 → $10 | Maintains | Market Perform |
| 03/09/2021 | 1508.39% | Barclays | → $23 | Initiates Coverage On | → Overweight |
| 03/02/2021 | 879.02% | Stifel | → $14 | Initiates Coverage On | → Hold |
| 11/11/2020 | 1788.11% | Berenberg | → $27 | Initiates Coverage On | → Buy |
| 10/13/2020 | 2277.62% | Morgan Stanley | $35 → $34 | Maintains | Overweight |
| 07/15/2020 | 2347.55% | Morgan Stanley | $37 → $35 | Maintains | Overweight |
| 03/31/2020 | 2487.41% | Morgan Stanley | $40 → $37 | Maintains | Overweight |
| 03/31/2020 | 809.09% | HC Wainwright & Co. | $35 → $13 | Downgrades | Buy → Neutral |
| 03/31/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 02/12/2020 | 2697.2% | Morgan Stanley | $37 → $40 | Maintains | Overweight |
| 11/11/2019 | 2137.76% | Wedbush | $43 → $32 | Maintains | Outperform |
| 10/28/2019 | 2347.55% | Nomura | → $35 | Initiates Coverage On | → Buy |
| 06/27/2019 | 1858.04% | Mizuho | → $28 | Initiates Coverage On | → Buy |
| 04/05/2019 | — | Janney Montgomery Scott | Initiates Coverage On | → Buy | |
| 11/28/2018 | 1788.11% | Leerink Swann | → $27 | Initiates Coverage On | → Market Perform |
| 09/17/2018 | 3186.71% | HC Wainwright & Co. | → $47 | Initiates Coverage On | → Buy |
| 08/13/2018 | 2697.2% | Morgan Stanley | $37 → $40 | Maintains | Overweight |
| 07/16/2018 | 2697.2% | Wells Fargo | → $40 | Initiates Coverage On | → Outperform |
| 07/16/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/16/2018 | 2557.34% | Wedbush | → $38 | Initiates Coverage On | → Outperform |
| 07/16/2018 | 2487.41% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
What is the target price for Avrobio (AVRO)?
The latest price target for Avrobio (NASDAQ: AVRO) was reported by Wells Fargo on July 13, 2023. The analyst firm set a price target for $2.00 expecting AVRO to rise to within 12 months (a possible 39.86% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Avrobio (AVRO)?
The latest analyst rating for Avrobio (NASDAQ: AVRO) was provided by Wells Fargo, and Avrobio maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Avrobio (AVRO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avrobio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avrobio was filed on July 13, 2023 so you should expect the next rating to be made available sometime around July 13, 2024.
Is the Analyst Rating Avrobio (AVRO) correct?
While ratings are subjective and will change, the latest Avrobio (AVRO) rating was a maintained with a price target of $2.50 to $2.00. The current price Avrobio (AVRO) is trading at is $1.43, which is out of the analyst's predicted range.